This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.
Signed informed consent
Age ≥ 19 years at the time of signing informed consent
Histological or clinical diagnosis of HCC according to the Korean Liver Cancer Association-National Cancer Center guidelines
HCC not amenable to curative treatment (e.g., surgical resection, local therapy, liver transplantation)
Fibrolamellar carcinoma or sarcomatoid carcinoma
Prior systemic therapy for HCC
Local therapy for HCC (including radiofrequency ablation, microwave ablation, cryoablation, transarterial chemoembolization, radioembolization, or radiotherapy) within 28 days prior to initiation of study treatment, or unresolved complications from such procedures
History of allogeneic stem cell or solid organ transplantation
National Cancer Center, Korea
Lead sponsor
Asan Medical Center
Collaborator
Seoul National University Hospital
Collaborator
Seoul National University Bundang Hospital
Collaborator
Samsung Medical Center
Collaborator
Hanyang University Guri Hospital
Collaborator